Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.

N/AWithdrawnNCT00820742

Pfizer

Overview

An open label, non-comparative, multicenter, non-interventional, post marketing surveillance study to evaluate the overall safety and tolerability of pegaptanib sodium(Macugen) in the treatment of Filipino patients with neovascular age-related macular degeneration based on incidence of adverse events and to evaluate the efficacy based on visual acuity, and the patient's and physician's overall satisfaction with tolerability and efficacy.

Open-label, non-comparative, non-interventional study

Study Type

OBSERVATIONAL

Conditions

Neovascular Age-related Macular Degeneration

Interventions

MacugenDRUG

Intravitreous injection of Pegaptanib Sodium 3.47 mg/mL solution every 6 weeks

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Must have at least one eye which was diagnosed with neovascular degeneration Exclusion Criteria: * Presence of other causes of choroidal neovascularization, including pathologic myopia (spherical equivalent of -8 diopters or more negative, or axial length of 25mm or more), ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, multifocal choroiditis

Outcomes

Primary Outcomes

Incidence of adverse events and serious adverse events

Time frame: 12 months

Secondary Outcomes

Mean change in visual acuity in the study eye at 6 months from baseline

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.